Back

Preclinical study and evaluation of S016, a novel oral small-molecule PCSK9 inhibitor

30 August 2026 (10:15 - 10:45)
Organised by: Logo
Congress Presentation Part of: New advancements in targeting atherogenic lipoproteins Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Guodong Cen

Sichuan University, Chengdu - Sichuan (China)

4 More presentations in this session

Presentation thumbnail
Long-term outcomes of beta-blockers in post-MI patients with mildly reduced or preserved left ventricular ejection fraction: a systematic review and meta-analysis
Doctor K. Hosseini (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Inclisiran in combination with statin therapy achieves profound LDL-C and lipoprotein(a) reduction without acute cardiovascular events in high-risk patients with familial hypercholesterolemia
Doctor K. Dyankov (Sofia, BG)
Abstract Slides
Presentation thumbnail
Efficacy of PCSK9 inhibitors in patients with peripheral artery disease: insights from the AT-TARGET-IT Registry
Doctor M. Di Santo (Naples, IT)
Abstract Slides
Presentation thumbnail
Apolipoprotein C-III inhibition reduces acute pancreatitis in familial chylomicronemia syndrome: a meta-analysis of randomized trials
Doctor K. Mahajan (Mandi, IN)

Access the full session

Session thumbnail
New advancements in targeting atherogenic lipoproteins

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Congress Presentation
AZD0780, a novel, oral PCSK9 inhibitor with properties allowing for broad use, food-intake independency and co-administration with other lipid lowering therapies
31 August 2025
thumbnail
Congress Presentation
VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C
29 August 2025
thumbnail
Congress Presentation
GLP1-RA associated with PCSK9i as chemosensitizing method and therapy of anthracycline-induced cardiotoxicity under exposure to Ox-LDL: biochemical and preclinical evidences
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources